# US 2026/0273105 A1 · Nucleic acid constructs and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0273105 A1
- Document ID: US20260273105A1
- Status: Published application
- Kind: A1
- Application number: 19/277,925
- Filed: 2025-07-23
- Published: 2026-09-17
- Earliest claimed: 2018-10-18
- Assignees: Intellia Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.
- Applicants: Intellia Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.
- Inventors: Jonathan Douglas Finn; Hon-Ren Huang
- Web page: https://patentgrep.com/patent/US20260273105A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 48/0041: {the non-active part being polymeric}
- C07K 14/765: Serum albumin, e.g. HSA
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/644: {Coagulation factor IXa (3.4.21.22)}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/1051: {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/86: Viral vectors
- C12Y 304/21022: Coagulation factor IXa (3.4.21.22)
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Nucleic acid constructs that allow insertion and/or expression of a sequence of interest, such as a transgene, are provided. Compositions and methods of using such constructs for expression of a polypeptide or therapeutic agent, for example, are also provided.

## Claims

### Claim at position 1

1-81. (canceled)

### Claim 82

A method of modifying a target locus in a human subject comprising providing a cell in the human subject with a bidirectional nucleic acid construct comprising:
a) a first segment comprising a first coding sequence for a therapeutic polypeptide; and
b) a second segment comprising a reverse complement of a second coding sequence for the therapeutic polypeptide,
wherein the first coding sequence and the second coding sequence are heterologous to the target locus and the bidirectional nucleic acid construct does not comprise: (i) a promoter that drives the expression of the first coding sequence, (ii) a promoter that drives the expression of the second coding sequence, and (iii) a homology arm, and
wherein expression of the first coding sequence or the second coding sequence produces the therapeutic polypeptide.

### Claim 83 (depends on 82)

The method of claim 82, wherein the second segment is 3′ of the first segment.

### Claim 84 (depends on 82)

The method of claim 82, wherein the second coding sequence for the polypeptide adopts a different codon usage from that of the first coding sequence for the polypeptide.

### Claim 85 (depends on 82)

The method of claim 82, wherein polyadenylation sequences are at the 3′ end of each of the first coding sequence and the second coding sequence.

### Claim 86 (depends on 85)

The method of claim 85, wherein the polyadenylation sequences comprise polyadenylation signal sequences or polyadenylation tail sequences.

### Claim 87 (depends on 82)

The method of claim 82, wherein the bidirectional nucleic acid construct comprises a splice acceptor site.

### Claim 88 (depends on 87)

The method of claim 87, wherein the bidirectional nucleic acid construct comprises a first splice acceptor site 5′ to the first segment and a second splice acceptor site 3′ to the second segment.

### Claim 89 (depends on 82)

The method of claim 82, wherein the bidirectional nucleic acid construct comprises one or more of the following terminal structures: hairpin, loops, inverted terminal repeats (ITR), or toroid.

### Claim 90 (depends on 82)

The method of claim 82, wherein the polypeptide is a secreted polypeptide.

### Claim 91 (depends on 82)

The method of claim 82, wherein the polypeptide, when expressed, comprises a heterologous signal peptide.

### Claim 92 (depends on 91)

The method of claim 91, wherein the heterologous signal peptide is an albumin signal peptide.

### Claim 93 (depends on 82)

The method of claim 82, wherein the bidirectional nucleic acid construct is administered to the human subject in an adeno-associated virus (AAV) vector.

### Claim 94 (depends on 93)

The method of claim 93, wherein the AAV vector is AAV2, AAV3, AAV3B, AAV5, AAV8, AAV9, AAV-DJ, AAV2/8, AAVrh10, or AAVLK03.

### Claim 95 (depends on 93)

The method of claim 93, wherein the AAV vector is a single stranded AAV (ssAAV) vector.

### Claim 96 (depends on 82)

The method of claim 82, wherein the cell is a liver cell.

### Claim 97 (depends on 96)

The method of claim 96, wherein the target locus is within human albumin intron 1.

### Claim 98 (depends on 97)

The method of claim 97, further comprising administering to the human subject a Cas9 nuclease and a guide RNA (gRNA) targeting human albumin intron 1; optionally wherein the gRNA is a single guide RNA (sgRNA); optionally wherein the Cas9 nuclease is administered as a protein or an mRNA encoding the Cas9 nuclease.

### Claim 99 (depends on 98)

The method of claim 98, wherein the Cas9 nuclease is a S. pyogenes Cas9, or a variant thereof.

### Claim 100 (depends on 98)

The method of claim 98, wherein the Cas9 nuclease induces a site-specific double-stranded (ds)DNA break within the human albumin intron 1 and the bidirectional nucleic acid construct is inserted into the human albumin intron 1 such that the first coding sequence or the second coding sequence is expressed by the liver cell.

### Claim 101

A viral vector comprising a bidirectional nucleic acid construct comprising:
a) a first segment comprising a first coding sequence for a therapeutic polypeptide; and
b) a second segment comprising a reverse complement of a second coding sequence for the therapeutic polypeptide,
wherein the first coding sequence and the second coding sequence are heterologous to the target locus and the bidirectional nucleic acid construct does not comprise: (i) a promoter that drives the expression of the first coding sequence, (ii) a promoter that drives the expression of the second coding sequence, and (iii) a homology arm.
